Aquilo Capital Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Aquilo Capital Management, LLC reported 10 stock positions worth $133.4 million. Its top holding was Arrowhead Pharmaceuticals (ARWR) at 19.5% of the portfolio, followed by Regenxbio (RGNX, 14.3%) and Blueprint Medicines (BPMC, 13.0%). Compared with Q4 2023, it opened 1 new position, added to 2 and reduced 5. The biggest buy was Regenxbio (RGNX, shares +13%) and the biggest sale Kymera Therapeutics (KYMR, shares −56%).
- Most Recent 13F
- Q3 2025
- Location
- SAN FRANCISCO, CA
- CIK
- 0001591986
- Portfolio Value
- $133.4M (Q1 2024)
- SEC Filing
- 0001591986-24-000005 ↗ filed May 15, 2024
Holdings Value
Holdings 10 stocks · $133.4M
| ARWR Arrowhead Pharmaceuticals Inc. | 19.47% | 908,474 | $26.0M | No change |
| RGNX Regenxbio Inc. | 14.31% | 906,248 | $19.1M | Add +12.9% |
| BPMC Blueprint Medicines Corp. | 12.95% | 182,151 | $17.3M | Reduce -28.5% |
| ARVN Arvinas Inc. | 12.55% | 405,766 | $16.8M | Reduce -17.1% |
| KYMR Kymera Therapeutics Inc. | 11.71% | 388,743 | $15.6M | Reduce -55.9% |
| SLN Silence Therapeutics PLC-ADR | 9.30% | 574,214 | $12.4M | Reduce -45.0% |
| MRUS Merus NV | 8.61% | 255,109 | $11.5M | Reduce -28.2% |
| STRO Sutro Biopharma Inc. Com SHS | 4.94% | 1,165,466 | $6.6M | Add +177.1% |
| DTIL Precision Biosciences Inc. | 3.92% | 385,440 | $5.2M | New |
| RPTX Repare Therapeutics Inc. | 2.24% | 633,271 | $3.0M | No change |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
Options Activity Q4 2023 → Q1 2024
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 200,000 | $17.9Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.